Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice

Neuropsychopharmacology

Volumn 34, Issue 7, 2009, Pages 1695-1709

  Basselin, Mireille ^a   Fox, Meredith A ^b   Chang, Lisa ^a   Bell, Jane M ^a   Greenstein, Dede ^c   Chen, Mei ^a   Murphy, Dennis L ^b   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Arachidonic acid; Deficient mice; Eicosanoids; Phospholipase A2; Serotonin; Serotonin transporter

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2; FENCLONINE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEAD TWITCH; MALE; MOUSE; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

AMPHETAMINES; ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACID; AUTORADIOGRAPHY; BODY WEIGHT; BRAIN; BRAIN MAPPING; CARBON ISOTOPES; CHROMATOGRAPHY, GAS; DINOPROST; DINOPROSTONE; FATTY ACIDS; FENCLONINE; HEAD MOVEMENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHOLIPASES A2, CYTOSOLIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; THROMBOXANE B2; WAKEFULNESS;

EID: 67349199691     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.227     Document Type: Article

References (75)

1. Alexandre C, Popa D, Fabre V, Bouali S, Venault P, Lesch KP et al (2006). Early life blockade of 5-hydroxytryptamine 1A receptors normalizes sleep and depression-like behavior in adult knockout mice lacking the serotonin transporter. J Neurosci 26: 5554-5564.
2. Anton RF, Wallis C, Randall CL (1983). In vivo regional levels of PGE and thromboxane in mouse brain: effect of decapitation, focused microwave fixation, and indomethacin. Prostaglandins 26: 421-429.
3. Baca-García E, Vaquero-Lorenzo C, Diaz-Hernandez M, Rodriguez-Salgado B, Dolengevich-Segal H, Arrojo-Romero M et al (2007). Association between obsessive-compulsive disorder and a variable number of tandem repeats polymorphism in intron 2 of the serotonin transporter gene. Prog Neuropsychopharmacol Biol Psychiatry 31: 416-420.
4. Basselin M, Chang L, Bell JM, Rapoport SI (2006a). Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31: 1659-1674.
5. Basselin M, Murphy DL, Rapoport SI (2007a). Increased brain arachidonic acid signaling can be imaged in vivo in serotonin transporter deficient mice: Basis for future clinical PET studies (abstract). Annual Meeting American College Neuropsychopharmacology, Boca Ratan, FL. 9-13 December 2007 Poster Session III Poster 123.
6. Basselin M, Villacreses NE, Chen M, Bell JM, Rapoport SI (2007b). Chronic carbamazepine administration reduces NMDA receptor-initiated signaling via arachidonic acid in rat brain. Biol Psychiatry 62: 934-943.
7. Basselin M, Villacreses NE, Langenbach R, Ma K, Bell JM, Rapoport SI (2006b). Resting and arecoline-stimulated brain metabolism and signaling involving arachidonic acid are altered in the cyclooxygenase-2 knockout mouse. J Neurochem 96: 669-679.
8. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A et al (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol Pharmacol 53: 649-655.
9. 2c receptor agonists. Ann N Y Acad Sci 861: 104-110.
10. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998b). Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54: 94-104.
11. Bosetti F (2007). Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J Neurochem 102: 577-586.
12. 2. J Neurochem 91: 1389-1397.
13. 2 knockout mouse. J Neurochem 87: 1471-1477.
14. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386-389.
15. Cesana R, Ceci A, Ciprandi C, Borsini F (1993). Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. J Pharm Pharmacol 45: 473-475.
16. 11C]-arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. Brain Res 755: 74-83.
17. 2. J Lipid Mediat Cell Signal 12: 83-117.
18. Demar Jr JC, Lee HJ, Ma K, Chang L, Bell JM, Rapoport SI et al (2006). Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats. Biochim Biophys Acta 1761: 1050-1059.
19. Demar Jr JC, Ma K, Chang L, Bell JM, Rapoport SI (2005). alpha-Linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid. J Neurochem 94: 1063-1076.
20. Esaki T, Cook M, Shimoji K, Murphy DL, Sokoloff L, Holmes A (2005). Developmental disruption of serotonin transporter function impairs cerebral responses to whisker stimulation in mice. Proc Natl Acad Sci USA 102: 5582-5587.
21. Esposito G, Giovacchini G, Liow J-S, Bhattacharjee AK, Greenstein D, Schapiro M et al (2008). Imaging neuroinflammation in Alzheimer disease with radiolabeled arachidonic acid and PET. J Nucl Med 49: 1414-1421.
22. Felder CC, Kanterman RY, Ma AL, Axelrod J (1990). Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc Natl Acad Sci USA 87: 2187-2191.
23. Fitzpatrick F, Soberman R (2001). Regulated formation of eicosanoids. J Clin Invest 107: 1347-1351.
24. Folch J, Lees M, Sloane Stanley GH (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
25. Fox MA, Andrews AM, Wendland JR, Lesch K-P, Holmes A, Murphy DL (2007a). A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. Psychopharmacology (Berl) 195: 147-166.
26. Fox MA, Jensen CL, French HT, Stein AR, Huang SJ, Tolliver TJ et al (2008a). Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology 201: 203-218.
27. Fox MA, Jensen CL, Gallagher PS, Murphy DL (2007b). Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. Neuropharmacology 53: 643-656.
28. 2A receptor interactions. Fundam Clin Pharmacol 22: S91.
29. Franklin KBJ, Paxinos G (1997). The Mouse Brain in Stereotaxic Coodinates. Academic Press, Inc.: San Diego.
30. Giovacchini G, Lerner A, Toczek MT, Fraser C, Ma K, DeMar JC et al (2004). Brain incorporation of [11C]arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. J Nucl Med 45: 1471-1479.
31. Gottschalk LA, Stone WM, Gleser GC, Iacono JM (1969). Anxiety and plasma free fatty acids (FFA). Life Sci 8: 61-68.
32. Holman RT (1986). Control of polyunsaturated acids in tissue lipids. J Am Coll Nutr 5: 183-211.
33. Homberg JR, Olivier JD, Smits BM, Mul JD, Mudde J, Verheul M et al (2007). Characterization of the serotonin transporter knockout rat: A selective change in the functioning of the serotonergic system. Neuroscience 146: 1662-1676.
34. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD et al (2006). Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78: 815-826.
35. 2A receptor function. Neuropharmacology 54: 776-783.
36. John TM, Viswanathan M, Etches RJ, Pilo B, George JC (1987). Influence of corticosterone infusion on plasma levels of catecholamines, thyroid hormones, and certain metabolites in laying hens. Poult Sci 66: 1059-1063.
37. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996). COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93: 2317-2321.
38. Lee HJ, Rao JS, Chang L, Rapoport SI, Bazinet RP (2008). Chronic N-methyl-D-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat. J Lipid Res 49: 162-168.
39. Lee HJ, Rao JS, Ertley RN, Chang L, Rapoport SI, Bazinet RP (2007). Chronic fluoxetine increases cytosolic phospholipase A2 activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl) 190: 103-115.
40. Li D, He L (2007). Meta-analysis supports association between serotonin transporter (5-HTT) and suicidal behavior. Mol Psychiatry 12: 47-54.
41. Li Q, Wichems CH, Ma L, Van de Kar LD, Garcia F, Murphy DL (2003). Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem 84: 1256-1265.
42. 2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther 278: 1373-1382.
43. Marques FZ, Hutz MH, Bau CH (2006). Influence of the serotonin transporter gene on comorbid disorders among alcohol-dependent individuals. Psychiatr Genet 16: 125-131.
44. Masoliver E, Menoyo A, Perez V, Volpini V, Rio ED, Perez J et al (2006). Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr Genet 16: 25-29.
45. Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM (2004). Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods 140: 169-181.
46. Motulsky H (2003). Prism 4 Statistics Guide-Statistical Analyses for Laboratory and Clinical Researchers. GraphPad Software Inc.: San Diego, pp 82-84.
47. Murphy DL, Fox MA, Timpano KR, Moya P, Ren-Patterson R, Andrews AM et al (2008). How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 55: 932-960.
48. Murphy DL, Lerner A, Rudnick G, Lesch KP (2004). Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv 4: 109-123.
49. Murphy DL, Lesch KP (2008). Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci 9: 85-96.
50. 2 in the normal rat brain. J Hirnforsch 39: 391-400.
51. 2 and cyclooxygenase-2 in Rhesus monkey cerebellum. Brain Res Mol Brain Res 116: 106-114.
52. 11C] DASB positron emission tomography study. Biol Psychiatry 62: 327-331.
53. Qu Y, Chang L, Klaff J, Seemann R, Greenstein D, Rapoport SI (2006). Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats. Eur Neuropsychopharmacol 16: 561-571.
54. 2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology (Berl) 180: 12-20.
55. 2 and its transcription factor, activator protein-2. J Neurochem 102: 1918-1927.
56. Rao JS, Lee HJ, Rapoport SI, Bazinet RP (2008). Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol Psychiatry 13: 585-596.
57. Rapoport SI (2001). In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci 16: 243-261.
58. Rapoport SI, Bosetti F (2002). Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 59: 592-596.
59. Rapoport SI, Chang MCJ, Spector AA (2001). Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 42: 678-685.
60. Robinson PJ, Noronha J, DeGeorge JJ, Freed LM, Nariai T, Rapoport SI (1992). A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: Review and critical analysis. Brain Res Brain Res Rev 17: 187-214.
61. Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E et al (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18: 1292-1301.
62. Rutkowska M, Jamontt J, Gliniak H (2006). Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 58: 200-206.
63. 2α regulates induction of brain cyclooxygenase-2 in a mouse model of inflammation. Am J Physiol Regul Integr Comp Physiol 288: R1774-R1782.
64. Serretti A, Benedetti F, Zanardi R, Smeraldi E (2005). The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 29: 1074-1084.
65. Shimizu T, Wolfe LS (1990). Arachidonic acid cascade and signal transduction. J Neurochem 55: 1-15.
66. Sokoloff L (1999). Energetics of functional activation in neural tissues. Neurochem Res 24: 321-329.
67. 1B autoreceptors in the enhancement of serotonin turnover in the mouse brain following repeated treatment with fluoxetine. Life Sci 71: 2867-2880.
68. Tabachnick BG, Fidell LS (2001). Computer-assisted research design and analysis. Allyn and Bacon: Boston (novol), pp 184-188.
69. Toborek M, Malecki A, Garrido R, Mattson MP, Hennig B, Young B (1999). Arachidonic acid-induced oxidative injury to cultured spinal cord neurons. J Neurochem 73: 684-692.
70. Uher R, McGuffin P (2008). The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry 13: 131-146.
71. Wendland JR, Moya PR, Kruse MR, Ren-Patterson RF, Jensen CL, Timpano KR et al (2008). A novel, putative gain-of-function haplotype at Slc6a4 associates with obsessive-compulsive disorder. Hum Mol Genet 17: 717-723.
72. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282: 699-706.
73. Xu J, Weng YI, Simonyi A, Krugh BW, Liao Z, Weisman GA et al (2002). Role of PKC and MAPK in cytosolic PLA2 phosphoryla-tion and arachadonic acid release in primary murine astrocytes. J Neurochem 83: 259-270.
74. 2α through nitric oxide-induced S-nitrosylation. Involvement of inducible nitric-oxide synthase and cycloox-ygenase-2. J Biol Chem 283: 3077-3087.
75. Zhang J, Goorha S, Raghow R, Ballou LR (2002). The tissue-specific, compensatory expression of cyclooxygenase-1 and -2 in transgenic mice. Prostaglandins Other Lipid Mediat 67: 121-135.